TrialPediatric nephrology (Berlin, Germany)2022

Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial.

Georgie Mathew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.